Table 1.

Characteristics of the included studies.

Study	Year	Country	Treatment	Study time	Sample size	Mean age (y)	Male	PLR cutoff value	Measurement index	Follow-up (median; months)	BCLC stage of patients
He and Lin et al.	2017	Chinese	TACE	2007.1–2015.7	216	53.05	200	94.62	NLR, PLR, PNI, PI, mGPS, NLR-PLR	14.4	A1 (23); A2 (4); A4 (9); B (98); C (82)
Yang et al.	2017	Chinese	Hepatectomy	2010.4–2013.10	778	51.98	671	150	PLR	NR	0/A (236); B/C (537)
Liu et al.	2016	Chinese	Hepatectomy	2004.7–2011.4	223	54	189	NR	PLR, NLR, APRI	NR	0/A (126); B/C (97)
Casadei et al.	2016	Italy	Sorafenib	2012–2015	56	NR	47	15.0	PLR, NLR, SII	NR	B (13); C (43)
Xue et al.	2016	Chinese	TACE	2007.1–2011.4	178	52.57	154	150	PLR	11.4	B (115); C (63)
Shiozawa et al.	2016	Japan	Sorafenib	2009.6–2015.1	16	67.5	12	ΔPLR% > 20%	NLR, PLR	NR	B (12); C (4)
Chan et al.	2015	Chinese	Hepatectomy	2001.1–2011.11	324	56.8	283	150	PLR, NLR, PNI	NR	A (324)
Xue et al.	2015	Chinese	TACE	2007.1–2011.3	291	53.05	258	150	PLR, NLR, PNI	NR	B (182); C (109)
Ni et al.	2015	Chinese	Hepatectomy	2010.12–2012.1	367	55	308	150 and 300	GPS, mGPS, NLR, PLR, PI, PNI	24	A (244); B (106); C (17)

TACE: transarterial chemoembolization; NR: not reported; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; PNI: prognostic nutritional index; PI: prognostic index; mGPS: modified Glasgow Prognostic Score; NLR-PLR: neutrophil/platelet-to-lymphocyte ratio; APRI: aspartate aminotransferase/platelet ratio index; SII: systemic immune-inflammation index; GPS: Glasgow Prognostic Score; PI: prognostic index.